Angioedema associated with Crohn's disease is a well described, but seldom seen phenomenon. However, clear diagnosis and management remains unclear. Vedolizumab is a humanized, monoclonal antibody that inhibits leukocyte adhesion and migration into the gastrointestinal tract via alpha4beta7 integrin antagonism. We report a case of Crohns-associated angioedema in a patient with prior quiescent disease on infliximab and his resolution of symptoms with transition to vedolizumab. A 19-year-old Caucasian male with terminal ileum and colonic Crohn's disease presented to our gastroenterology clinic with progressive facial swelling, primarily of the lips and eyelids. His symptoms and mucosal disease had previously been well controlled on infliximab 10 mg/kg every 8 weeks and azathioprine 2.5 mg/kg daily combination therapy. However, over the next 6 months his symptoms began resurfacing approximately 4 weeks after infliximab infusions. Further evaluation ruled out hereditary angioedema and symptoms of facial swelling would quickly dissipate with subsequent infliximab infusions only to return within weeks. Mucosal evaluation 4 weeks post-infliximab revealed moderate pan-colitis and the patient was consequently transitioned to vedolizumab therapy. Within 4 weeks of starting vedolizumab infusions, the patient had complete resolution of angioedema in addition to complete mucosal healing on follow-up colonoscopy. This case highlights chronic idiopathic angioedema associated with Crohn's disease successfully treated with an anti-integrin agent.